Login / Signup

Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.

Pamela AbdayemNathalie IbrahimYolla El DakdoukiChristophe WillekensDavid GhezJulia A RouchePeggy DartiguesRomain DesmarisAlina DanuJulien RossignolJulien LazaroviciChristophe FerméVincent RibragJean Marie Michot
Published in: European journal of haematology (2021)
R-mini-CYVE demonstrated a meaningful antitumour efficacy and an acceptable safety profile in patients with relapsed/refractory B-cell NHL who were ineligible for HDT.
Keyphrases
  • hodgkin lymphoma
  • diffuse large b cell lymphoma
  • acute myeloid leukemia
  • high dose
  • acute lymphoblastic leukemia
  • multiple myeloma
  • low dose
  • locally advanced
  • squamous cell carcinoma
  • rectal cancer